



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

Daily 8.VII.2022

Company	LT fundamental recommendation	12M EFV (PLN)	ST market-relative bias	Analyst
BioMaxima	Not rated	37.3	Not rated	Sylvia Jaśkiewicz, CFA Mikołaj Stępień

Event: the share buy-back program

Yesterday, during the WSE trading, the Company informed that since the end of June it had purchased 9,817 shares (0.2268% of shares/votes) for PLN 247,400 within the framework of the pending buy-back. The average purchase price per share was PLN 25.21. To date, out of PLN 5 million allocated for the buy-back almost 5% have been spent.

Expected impact: the information is in line with previous announcements.

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.